Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases

Tumori

Volumn 84, Issue 1, 1998, Pages 39-44

  Fontana, Dario ^a   Bertetto, Oscar ^b   Fasolis, Giuseppe ^a   Berruti, Alfredo ^a   Tarabuzzi, Roberto ^a   Pagani, Giovanni ^c   Buniva, Tiziana ^a   Zolfanelli, Roberto ^d   Pallotti, Silvio ^e   Frezzotti, Letizia ^f   Bumma, Cesare ^b   Rocca Rossetti, Salvatore ^b   Dogliotti, Luigi ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c San Biagio Hospital   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e USL 20   (Italy)

^f ZENECA   (Italy)

Author keywords

Goserelin; Mitomycin C; Prostate cancer; Prostate specific antigen

Indexed keywords

GOSERELIN; MITOMYCIN C; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031921815     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400108     Document Type: Article

References (20)

1. Berruti A., Fara E., Fasolis G., Randone D., Bertetto O., Tarabuzzi R., Mosele G., Fontana D., Rocca Rossetti S., Dogliotti L.: Somministrazione orale di estramustina ed etoposide nel trattamento di pazienti con carcinoma prostatico avanzato in progressione dopo soppressione androgenica. Forum Trends Exp. Clin. Med., 6: 63-67, 1996.
2. Boccardo F., Granetto C.: Chemotherapy in advanced stage prostate cancer: an overview. Forum Trends Exp. Clin. Med., 5 (suppl 4): 42-45, 1995.
3. Eisenberger M., Crawford E.D., McLeod D., Hussain M., Loehrer P., Blumenstein B.: The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC): interim evaluation of intergroup study 0105. Proc. Am. Soc. Clin. Oncol., 14: 235, 1995.
4. Fossa S.D., Aass N., Opjordsmoen S.: Assessment of quality of life in patients with prostate cancer. Semin. Oncol., 21: 657-661, 1994.
5. Gibbons R.P.: Prostate cancer. Chemotherapy. Cancer, 60: 586-588, 1987.
6. Griffiths K., Eaton C.L., Harper M.E., Turkes A., Peeling W.B.: Hormonal treatment of advanced disease: some newer aspects. Semin. Oncol., 21: 672-687, 1994.
7. Huben R.P., Murphy G.P.: A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer, 62: 1881-1887, 1988.
8. Isaacs J.T., Coffey D.S.: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res., 41: 5070-5075, 1981.
9. Isaacs J.T.: The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate, 5: 1-17, 1984.
10. Jones W.G., Fossa S.D., Bono A.V., Croies J.J., Stoter G., De Pauw M., Sylvester R.: Mitomycin C in metastatic prostate cancer. Report on an EORTC phase II study. World J. Urol., 4: 182-185, 1986.
11. Kubota Y., Nakada T., Imai K., Yamanaka H., Sakai H., Saito Y., Tomaru Y., Kitamura K., Sugano O., Sasagawa I.: Chemoendocrine therapy in patients with stage D2 prostate cancer. Prostate, 26: 50-54, 1996.
12. Melzack R.: A McGill pain questionnaire: major properties underscoring methods. Pain, 1: 277-299, 1975.
13. Miller J.I., Ahman F.R., Drach D.W., Emerson S.S., Bottaccini M.R.: The clinical usefulness of serum prostate-specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol., 147: 956-961, 1992.
14. Murphy G.P., Beckley S., Brady M.F., Chu M., deKernion J., Dhabuwala C., Gaeta J.F., Gibbons R.P., Loening S.A., McKiel C.F., McLeod D.G., Pontes E., Prout G.R., Schmidt J.D., Scott W.W., Slack N.H., Soloway M.S.: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer, 51: 1264-1272, 1983.
15. Murphy G.P., Huben R.P., Priore R.: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology, 28: 36-40, 1986.
16. Pienta K.J., Redman B., Hussain M., Cummings G., Esper P.S., Appel C., Flaherty L.E.: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adeno-carcinoma of the prostate. J. Clin. Oncol., 12: 2005-2012, 1994.
17. Rosso S., Patriarca S., Vicari P., Zanetti R.: Cancer incidence in Turin: the effect of migration. Tumori, 79: 304-310, 1993.
18. SAS 6.08 VM/CMS, SAS Institute Inc, SAS Campus Drive, Cary, NC 27513.
19. Takayama T.K., Vessella R.L., Lange P.H.: Newer application of serum prostate-specific antigen in the management of prostate cancer. Semin. Oncol., 21: 542-553, 1994.
20. Vandenbroucke F., Van Poppel H., Derluyn J., Popelier G., Casselman J., Billiet I., Vanuytsel L., Paridaens R., Baert L.: Interim results on a randomized trial of mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer. Am. J. Clin. Oncol. (CCT), 18: 263-266, 1995.